Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo

Lihua Yang, Erin Jackson, B. Mark Woerner, Arie Perry, David Piwnica-Worms, Joshua B. Rubin

Research output: Contribution to journalArticlepeer-review

129 Scopus citations


The chemokine CXCL12 and its cognate receptor CXCR4 regulate malignant brain tumor growth and are potential chemotherapeutic targets. However, the molecular basis for CXCL12-induccd tumor growth remains unclear, and the optimal approach to inhibiting CXCR4 function in cancer is unknown. To develop such a therapeutic approach, we investigated the signaling pathways critical for CXCL12 function in normal and malignant cells. We discovered that CXCL12-dependent tumor growth is dependent upon sustained inhibition of cyclic AMP (cAMP) production, and that the antitumor activity of the specific CXCR4 antagonist AMD 3465 is associated with blocking cAMP suppression. Consistent with these findings, we show that pharmacologic elevation of cAMP with the phosphodiesterase inhibitor Rolipram suppresses tumor cell growth in vitro and, upon oral administration, inhibits intracranial growth in xenograft models of malignant brain tumors with comparable efficacy to AMD 3465. These data indicate that the clinical evaluation of phosphodiesterase inhibitors in the treatment of patients with brain tumors is warranted.

Original languageEnglish
Pages (from-to)651-658
Number of pages8
JournalCancer research
Issue number2
StatePublished - Jan 15 2007


Dive into the research topics of 'Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo'. Together they form a unique fingerprint.

Cite this